AfterRaise/Companies/Trellis Bioscience

Trellis Bioscience

Trellis Bioscience is a clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases. From its funding announcement.

$9M Series CRaised 3 months agoRedwood City, USABiotech & PharmaUSA
Visit website →

In their own words

What Trellis Bioscience says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Trellis Bioscience is today

Trellis Bioscience announced a Series C round of $9M on 20 July 2026, led by New Science Ventures and Easton Capital.

Latest round
Series C
Amount
$9M
Announced
20 July 2026
Headquarters
Redwood City, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Also participating
Not stated
Relevant leadership
CEO Geoff Dillon

Momentum AfterRaise intelligence

AfterRaise Score

56
Steady growth
1 funding signal in the last 90 days
Funding recency
28/40
announced within the last 90 days
Round scale
8/25
round size relative to the market
Funding stage
20/20
Series C
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 20 July 2026
    $9M Series C
    Led by New Science Ventures and Easton Capital.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Multi-market operations
  • Executive appointments

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 20 July 2026$9M Series C announced
  • 20 July 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Trellis Bioscience is open to

Not yet specified

Trellis Bioscience has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Trellis Bioscience

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Trellis Bioscience?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector